TG4010

Home/TG4010

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model

Christelle Remy-Ziller, et al. Human Vaccines & Immunotherapeutics, 2017, 19:0 [...]

By |2019-07-01T17:22:57+02:00October 12th, 2017|Publication, TG4010|Comments Off on Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model

Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer

20170425 BMS-Clinical Collaboration Release Transgene-FINAL

By |2019-06-03T19:57:09+02:00April 25th, 2017|Press release, TG4010|Comments Off on Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer

UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) / The trial will be supported by Transgene and Bristol-Myers Squibb

UC Davis to Conduct Phase 2 Trial of the Combination [...]

By |2019-06-03T20:04:01+02:00December 7th, 2016|Press release, TG4010|Comments Off on UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) / The trial will be supported by Transgene and Bristol-Myers Squibb